Journal
PROCESSES
Volume 9, Issue 4, Pages -Publisher
MDPI
DOI: 10.3390/pr9040574
Keywords
drug release; excipients; mefenamic acid; nanosuspension; pediatric delivery; stability
Categories
Funding
- Deanship of Scientific Research (DSR) at King Saud University, Riyadh, Saudi Arabia [RGP-1438-013]
Ask authors/readers for more resources
This study investigated the feasibility of preparing mefenamic acid (MA) oral nanosuspension using nanosuspension technology. By optimizing techniques and excipients, a stable nanosuspension with small particle size and excellent biocompatibility was successfully developed.
Molecules with poor aqueous solubility are difficult to formulate using conventional approaches and are associated with many formulation delivery issues. To overcome these obstacles, nanosuspension technology can be one of the promising approaches. Hence, in this study, the feasibility of mefenamic acid (MA) oral nanosuspension was investigated for pediatric delivery by studying the role of excipients and optimizing the techniques. Nanosuspensions of MA were prepared by adopting an antisolvent precipitation method, followed by ultrasonication with varying concentrations of polymers, surfactants, and microfluidics. The prepared nanosuspensions were evaluated for particle size, morphology, and rheological measures. Hydroxypropyl methylcellulose (HPMC) with varying concentrations and different stabilizers including Tween(R) 80 and sodium dodecyl sulfate (SLS) were used to restrain the particle size growth of the developed nanosuspension. The optimized nanosuspension formula was stable for more than 3 weeks and showed a reduced particle size of 510 nm with a polydispersity index of 0.329. It was observed that the type and ratio of polymer stabilizers were responsive on the particle contour and dimension and stability. We have developed a biologically compatible oral nanoformulation for a first-in-class drug beautifully designed for pediatric delivery that will be progressed toward further in vivo enabling studies. Finally, the nanosuspension could be considered a promising carrier for pediatric delivery of MA through the oral route with enhanced biological impact.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available